Home > Insider Trading > Filing (0000950170-24-025083)

Filing Details

Accession Number:: 0000950170-24-025083
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-04 18:12:04
Reporting Period:: 2024-03-01

Accepted Time:: 2024-03-04 18:12:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1815442	Kymera Therapeutics Inc.	KYMR	Biological Products, (No Disgnostic Substances) (2836)	812992166

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1821074	N. Bruce Jacobs	C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472	Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-01	31,250	$0.00	146,285	No	4	A	Direct
Common Stock	Disposition	2024-03-04	2,378	$41.41	143,907	No	4	S	Direct
Common Stock	Disposition	2024-03-04	1,301	$42.39	142,606	No	4	S	Direct
Common Stock	Disposition	2024-03-04	255	$43.26	142,351	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-03-01	187,500	$0.00	187,500	$43.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
187,500		2034-02-28	No	4	A	Direct

Footnotes

Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.
Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.